Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
Blood Adv. 2022 Feb 22;6(4):1089-1094. doi: 10.1182/bloodadvances.2021006119.
Blood Adv. 2022.
PMID: 34794179
Free PMC article.
Clinical Trial.